NCT00982774已完成1 期
Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL
Access to Advanced Health Institute (AAHI)1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2009年4月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Evaluate the safety of the vaccine given as 3 sc injections every 14 days in combination with standard SSG therapy in patients with persistent PKDL.
研究概览
简要总结
A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard chemotherapy with sodium stibogluconate (20 mg/kg/day for 40 days) in patients with PKDL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 7 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females = 7 years and < 40 years of age.
- •Must have a skin rash of > 6 months duration compatible with a diagnosis of PKDL following a history of successful treatment of VL, and histopathology consistent with PKDL (Section 6.1).
- •Female patients of child bearing age must have a negative serum pregnancy test at screening, a negative urine pregnancy test within 24 hours before study injection, must not be breast-feeding, and are required to use adequate contraception through Day 59 of the study. These precautions are necessary due to unknown effects that LEISH-F2 + MPL-SE might have in a fetus or newborn infant.
- •The following laboratory blood tests must have values within the normal ranges at screening (Appendix 3): sodium, potassium, urea, total bilirubin, glucose, creatinine, hemoglobin and platelet count. ALT, AST, alkaline phosphatase, and total WBC count values (commonly elevated in PKDL patients) must be below grade 2 at screening (Appendix 3).
- •The following serology tests must be negative at screening: HIV 1/2 (in patients >14 years of age), hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All patients (or their parents) will receive HIV-related counseling prior to testing. Patients with positive HIV test results will receive counseling at the University and will be referred to the national AIDS control program for treatment if appropriate.
- •Normal ECG.
- •Potential study patients (or their guardians) must give written informed consent, be willing to be admitted to hospital for a minimum of 40 days and up to 60 days, able to attend all required follow-up visits, have a permanent address, and be reachable by study site personnel.
排除标准
- •Presence of other skin conditions.
- •Anti-leishmanial treatment within the past 30 days.
- •History of previous exposure to Leishmania vaccines.
- •Known use of injected or oral corticosteroids within 6 weeks prior to the first administration of study injection.
- •Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first administration of study injection.
- •History of autoimmune disease or other causes of immunosuppressive states.
- •History or evidence of any acute or chronic illness that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Patients presenting with concomitant illness will be referred for standard clinical care).
- •History of use of any medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.
- •History of significant psychiatric illness.
- •Known to be a current drug or alcohol abuser.
- •Patients with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.
- •Patients who are unlikely to cooperate with the requirements of the study protocol.
- •Known allergy or contraindication to SSG.
- •Regardless of eligibility, standard clinical care will be provided (at no cost to the patient) to all PKDL patients screened for participation in the study.
结局指标
主要结局
Evaluate the safety of the vaccine given as 3 sc injections every 14 days in combination with standard SSG therapy in patients with persistent PKDL.
时间窗: one year
次要结局
- Assess the effect of the vaccine on the clinical course of PKDL.(one year)
- To evaluate the immunogenicity of the vaccine by evaluating antibody and T-cell responses to the LEISH-F2 protein and Soluble Leishmania Antigen (SLA).(one year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy SubjectsHealthy VolunteersNCT02934269Celgene40
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult SubjectsLassa Virus InfectionHealthy Adult ParticipantsNCT05735249Arisan Therapeutics, Inc.94
已完成
1 期
A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly ParticipantsHealthyNCT06391827Dong-A ST Co., Ltd.90
终止
1 期
Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy SubjectsDiabetesNCT05330208Beijing Suncadia Pharmaceuticals Co., Ltd60
已完成
1 期
Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy SubjectsSARS CoV 2 InfectionNCT05523141Ascletis Pharmaceuticals Co., Ltd.72